CD79b-targeted antibody-drug conjugate 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 
80 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Polivy (polatuzumab vedotin-piiq) / Roche
ChiCTR2300077262: A single-arm, multicenter, exploratory study of Polatuzumab Vedotin for injection in combination with Rituximab, Cyclophosphamide, Pirarubicin, and Prednisone in the initial treatment of diffuse large B-cell lymphoma

Recruiting
4
76
 
Polatuzumab Vedotin for Injection 1.8mg/kg, d0Rituximab 375mg/m2, d0Cyclophosphamide 750mg/m2, d1Pirarubicin 50mg/m2, d1Prednisone 100mg, d1-5
Shanxi Cancer Hospital; Shanxi Cancer Hospital, Shanxi Society of Geriatrics
Diffuse large B lymphoma
 
 
2019-002962-10: An unblinded study to compare the treatment success and tolerability of a chemotherapy consisting of a combination of rituximab, ifosfamide, carboplatin and etoposide with and without the addition of polatuzumab vedotin in subject suffering from an aggressive lymphoma, a malignant disease of the lymphatic system.

Not yet recruiting
3
334
Europe
Polivy, Mabthera, Ifosfamide, Carboplatin, Etoposide, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for injection/infusion, Polivy, MABTHERA®
GWT-TUD GmbH, F. Hoffmann-La Roche Ltd
primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), patients whose cancer of the lymph nodes has returned or not responded to treatment, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
POLARIX, NCT03274492 / 2017-002023-21: A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

Hourglass Apr 2023 - Apr 2023 : Anticipated approval in combination with Rituxan plus cyclophosphamide, doxorubicin & prednisone for 1L DLBCL based on POLARIX trial
Hourglass Apr 2022 - Dec 2022 : Submission in US for 1L DLBCL
Checkmark Updated data from POLARIX trial for 1L DLBCL at ASH 2022
Dec 2022 - Dec 2022: Updated data from POLARIX trial for 1L DLBCL at ASH 2022
Checkmark Presentation of POLARIX trial in 1L DLBCL at ASH 2022
More
Active, not recruiting
3
1000
Europe, Canada, Japan, US, RoW
Polatuzumab Vedotin, DCDS4501A; anti-CD79b-VC-MMAE, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Vincristine Placebo, Prednisone, Polatuzumab vedotin Placebo
Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma
07/26
07/26
POTENT, NCT06522555: The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma

Recruiting
3
100
RoW
polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide, zanubrutinib, rituximab and lenalidomide
Ruijin Hospital
Diffuse Large B-Cell Lymphoma
08/28
08/29
POLARGO, NCT04182204 / 2018-003727-10: A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting
3
270
Europe, Canada, US, RoW
Polatuzumab Vedotin, Rituximab, Mabthera; Rituxan, Gemcitabine, Oxaliplatin
Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma
11/24
03/25
Pola-R-ICE, NCT04833114 / 2019-002962-10: Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide () Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Active, not recruiting
3
306
Europe
Polatuzumab Vedotin, Mabthera, Ifosfamide, Carboplatin, Etoposide
GWT-TUD GmbH, Hoffmann-La Roche
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
12/26
12/27
SUNMO, NCT05171647: A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Calendar Jan 2025 - Dec 2026: Submission in US in combination with Lunsumio for 2L DLBCL
Jan 2023 - Dec 2024: Data from SUNMO trial in combination with polivy for 2L+ DLBCL
Active, not recruiting
3
242
Canada, Japan, US, RoW
Mosunetuzumab, Polatuzumab vedotin, Tocilizumab, Rituximab, Gemcitabine, Oxaliplatin
Hoffmann-La Roche
Non-Hodgkin Lymphoma
05/25
02/27
SKYGLO, NCT06047080: An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Recruiting
3
1130
Europe, Canada, Japan, US, RoW
Glofitamab, Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
Hoffmann-La Roche
Large B-Cell Lymphoma
06/26
02/29
jRCT2080223990: A phase II Study of Polatuzumab Vedotin in Combination with Rituximab plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Completed
2
35
Japan
Polivy (polatuzumab vedotin-piiq) - Roche, bendamustine - Generic mfg., Rituxan (rituximab) - Roche
CHUGAI PHARMACEUTICAL CO., LTD.
B cell Non-Hodgkin Lymphoma
 
 
2019-000842-36: Polatuzumab vedotin combined with standard chemo-immunotherapy drugs in diffuse large B-cell lymphoma

Not yet recruiting
2
56
Europe
Polatuzumab Vedotin, Lyophilisate for solution for infusion
The Clatterbridge Cancer Centre NHS Foundation Trust, Roche Products Ltd
Diffuse large B-cell lymphoma in patients with co-morbidities who cannot tolerate full dose R-CHOP., A cancer of the blood affecting B-cells., Diseases [C] - Cancer [C04]
 
 
2021-000468-32: Study for patients with mantle cell lymphoma (one type of lymphomas = lymph node cancer), aimed to answer the question if patients who relapse after previous therapy with Bruton tyrosine kinase inhibitor (type of biologivcal treatment) will be beneficiary adding of polatuzumab vedotin (new type of biological treatment) to commonly used treatment with bendamustine and rituxima (combination of chemotherpay and biological treatment) Studie pro pacienty s lymfomem z plášťových buněk (jeden z podtypů lymfomu), která se snaží odpovědět na otázku, zda u pacientů, u kterých selhala předchozí léčba inhibitory Brutonovy kinázy (typ biologické léčby), bude přinosem přidání polatuzumab vedotinu (nový typ biologické léčby) k již běžně používané záchranné léčbě (kombinace bendamustinu a rituximabu (tj. chemoterapie a biologické léčby)

Not yet recruiting
2
21
RoW
Polatuzumab vedotin, Bendamustine Accord 25 mg/ml, Mabthera, RO5541077, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Polivy, Bendamustine Accord, Mabthera
Kooperativní lymfomová skupina, z.s., Kooperativní lymfomová skupina, z.s.
Mantle cell lymphoma lymfom z plášťových buněk, aggressive lymph node cancer of B-cell origin agresivní nádorové onemocnění z mízních uzlin z B-buněk, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2021-006030-40: EFFICACY OF POLATUZUMAB, BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MANTLE CELL LYMPHOMA

Not yet recruiting
2
16
Europe
Powder for solution for infusion, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Polivy, Bendamustin Accord, MabThera
Med. Univ. Wien, Klinik f. Innere Med I, Onkologie
MANTLE CELL LYMPHOMA, MANTLE CELL LYMPHOMA, Diseases [C] - Cancer [C04]
 
 
2022-003398-51: A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dose R-CHOP Eine prospektive, multizentrische Phase-2-Studie zur chemotherapiearmen Kombination von Rituximab mit dem Antikörper-Wirkstoff-Konjugat Polatuzumab Vedotin und dem bispezifischen Antikörper Glofitamab bei zuvor unbehandelten Patienten mit aggressivem B-Zell-Lymphom über 60 Jahren, die für ein voll dosiertes R-CHOP nicht in Frage kommen

Not yet recruiting
2
80
Europe
Glofitamab, Obinutuzumab, Polatuzumab vedotin, Rituximab, RO7082859, RO5072759, RO5541077, RO0452294, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Columvi, GAZYVARO, Polivy, MabThera
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Roche Pharma AG, Roche Austria GmbH
aggressive large B-cell lymphoma, aggressive large B-cell lymphoma, Diseases [C] - Cancer [C04]
 
 
NCT06468943: Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Enrolling by invitation
2
20
RoW
Polatuzumab Vedotin, Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
The First Affiliated Hospital of Soochow University
Effects of Chemotherapy, Safety Issues
05/26
05/28
2022-PUMCH-A-194, NCT06176729: Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

Recruiting
2
30
RoW
Polatuzumab Vedotin, Rituximab, Lenalidomide
Yan Zhang, MD, Peking University Third Hospital, Peking University First Hospital, Chinese PLA General Hospital
Diffuse Large B Cell Lymphoma
10/25
10/27
NCT04479267: Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

Recruiting
2
49
US
Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione, 53-03-2, Adasone, Cortancyl, Dacortin, , Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Prednisolone, (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, .delta.1-Hydrocortisone, 1,2-Dehydrohydrocortisone, 50-24-8, 9120, Adnisolone, Aprednislon, Capsoid, Cortalone, Cortisolone, Methylprednisolone, (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione, 6Alpha-Methylprednisolone, Adlone, Caberdelta M, DepMedalone, Depo Moderin, Depo-Nisolone, Duralone, Emmetipi, Esametone, Rituximab, 174722-31-7, 687451, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, Polatuzumab Vedotin, 1313206-42-6, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, POLATUZUMAB VEDOTIN, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Cyclophosphamide, 1-bis(2-chloroethyl)-amino-1-oxo-2-aza-5-oxaphosphoridin monohydrate, 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, Doxorubicin Hydrochloride, 14-Hydroxydaunorubicin Hydrochloride, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements, Double Expressor Lymphoma, High-grade B-cell Lymphoma
11/25
11/26
NCT04665765: Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting
2
41
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
City of Hope Medical Center, National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma Unclassifiable, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
07/22
07/25
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
01/25
07/29
NCT04594798: A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients with DLBCL

Recruiting
2
39
US
Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
University of Rochester, Genentech, Inc.
DLBCL, Lymphoma, B-Cell
07/26
07/26
NCI-2021-12489, NCT05169658: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Active, not recruiting
2
42
US
Mosunetuzumab, 1905409-39-3, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, RG 7828, RG-7828, RG7828, RO7030816, Lunsumio, Mosunetuzumab-axgb, Obinutuzumab, 949142-50-1, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Polatuzumab Vedotin, 1313206-42-6, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, FDG-Positron Emission Tomography, FDG-PET, FDG-PET Imaging, Computed Tomography, CT Scan, CAT Scan, Computed Axial Tomography, Positron Emission Tomography, PET scan, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, Biological Sample Collection
University of Washington, Genentech, Inc.
Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
03/25
03/25
NCT06530511: Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL

Recruiting
2
30
RoW
Polatuzumab vedotin, Rituximab, Orelabrutinib
Affiliated Hospital of Nantong University
Diffuse Large B Cell Lymphoma
02/26
08/26
NCT06554600: A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
36
RoW
Zanubrutinib, Polatuzumab Vedotin, Bendamustine, Rituximab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Refractory or Relapsed Diffuse Large B Cell Lymphoma
08/26
08/28
NCT06453044: Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed or Refractory Grade 1-3a Follicular Lymphoma

Recruiting
2
41
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Questionnaire Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma
03/28
03/28
2024-SR-436, NCT06516978: A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Not yet recruiting
2
528
NA
Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Orelabrutinib, Venetoclax, Chidamide, Penpulimab, Lenalidomide
The First Affiliated Hospital with Nanjing Medical University
Diffuse Large B Cell Lymphoma
10/28
04/29
NCT06664411: Pola-ZR2P in Previously Untreated DLBCL

Not yet recruiting
2
80
RoW
Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy, Pola-ZR2P
Navy General Hospital, Beijing
Diffuse Large B-cell Lymphoma
12/29
12/30
NCT05633615: Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
396
US
Axicabtagene Ciloleucel, KTE C19, KTE-C19, KTE-C19 CAR, Yescarta, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Lisocabtagene Maraleucel, Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017, Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017, Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017, Breyanzi, JCAR 017, JCAR017, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, RG 7828, RG-7828, RG7828, RO7030816, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tisagenlecleucel, CART-19, CART19, CTL019, CTL019 T-cells, Kymriah, Tisagenlecleucel-T
SWOG Cancer Research Network, National Cancer Institute (NCI), Genentech, Inc.
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
12/25
12/29
GUIDANCE-005, NCT06441097: Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Not yet recruiting
2
152
NA
Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone, Acalabrutinib, Lenalidomide, Decitabine
Ruijin Hospital
Diffuse Large B-Cell Lymphoma
12/27
12/27
NCT06665217: G-Pola-ZLP in Diffuse Large B-Cell Lymphoma

Not yet recruiting
2
80
NA
Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy, G-Pola-ZLP
Navy General Hospital, Beijing
Diffuse Large B-Cell Lymphoma
01/29
01/30
GLORY, NCT06765317: A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

Recruiting
2
42
US
Glofitamab, Polatuzumab, Rituximab, Cyclophosphamide, Doxorubicin, Obinutuzumab:
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma
01/28
01/28
NCT06743945: POLA-R-CHP in the First-line Treatment of Transformed DLBCL

Recruiting
2
20
RoW
POLA-R-CHP, polatuzumab vedotin and R-CHP
Fudan University
Transformed Lymphoma
12/27
12/29
GUIDANCE05, NCT06803693: Efficacy and Safety of Pola-RCHP-X Vs Pola-RCHP in Untreated DLBCL

Not yet recruiting
2
152
NA
Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone, Zanubrutinib, Lenalidomide, Decitabine
Ruijin Hospital
Diffuse Large B-Cell Lymphoma
04/28
12/28
NCT06890884: A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBL) (MK-2140-011/waveLINE-011)

Not yet recruiting
2
594
NA
Zilovertamab vedotin, MK-2140, VLS-101, Rituximab, RITUXAN®, Cyclophosphamide, CYTOXAN®, NEOSAR®, Doxorubicin, ADRIAMYCIN®, Rituximab Biosimilar, TRUXIMA®, RUXIENCE®, RIABNI®, Prednisone, Prednisolone, Polatuzumab vedotin
Merck Sharp & Dohme LLC
Lymphoma, Large B-Cell, Diffuse
12/27
12/32
NCT06594939: Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Not yet recruiting
2
31
US
Polatuzumab Vedotin, Polivy, Mosunetuzumab, Lunsumio, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Prednisone, Pegfilgrastim, filgrastim
Medical College of Wisconsin
Diffuse Large B Cell Lymphoma (DLBCL)
06/28
12/29
NCT05940051: Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
35
RoW
Zanubrutinib, Polatuzumab vedotin and Rituximab
Peng Liu
Diffuse Large B Cell Lymphoma
07/25
12/25
SHZS-DLBCL003, NCT05940064: Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma

Recruiting
2
30
RoW
Zanubrutinib, Polatuzumab Vedotin, Rituximab, ZPR
Peng Liu
Diffuse Large B Cell Lymphoma
07/25
12/25
NCT05615636: A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Recruiting
2
36
US
Mosunetuzumab, RO7030816, Polatuzumab vedotin, Tafasitamab, Lenalidomide, CC-5013, Revlimid
M.D. Anderson Cancer Center
Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL
08/25
08/27
NCT04679012: Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Recruiting
2
20
US
Polatuzumab Vedotin, Polivy, Rituximab, Rituxan, chimeric anti-CD20 monoclonal antibody, Etoposide, VP-16, VePesid, etopophos, toposar, Prednisone, Deltasone, Orasone, Paracort, Cortan, Cyclophosphamide, cytoxan, Hydroxydaunomycin, Doxorubicin Hydrochloride, Hydroxydoxorubicin Hydrochloride
Weill Medical College of Cornell University, Genentech, Inc.
Richter Syndrome, Chronic Lymphocytic Leukemia
09/25
09/26
GRAIL, NCT06050694: Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL

Not yet recruiting
2
40
Canada
glofitamab
University Health Network, Toronto
Diffuse Large B Cell Lymphoma (DLBCL)
11/25
11/27
NCT05260957: CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

Recruiting
2
22
US
Mosunetuzumab, BTCT4465A, Polatuzumab, Polatuzumab Vedotin, RO5541077, Polivy, CAR-T Cell Therapy, Chimeric antigen receptor T-Cell Therapy
Lazaros Lekakis, Genentech, Inc.
Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma
12/25
12/27
CLSGMCLPOLA, NCT04913103: Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL

Not yet recruiting
2
21
RoW
Polatuzumab vedotin, Polivy, Bendamustine Hydrochloride, Bendamustine Accord, Bendamustine Glenmark, Bendamustine KABI, Rituximab, Mabthera, Rixathon, Truxima
Czech Lymphoma Study Group
Lymphoma, Mantle-Cell
08/26
08/27
NCT05800366: A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients with High-risk Diffuse Large B-cell Lymphoma

Active, not recruiting
2
41
US
Glofitamab, RO7082859, Polatuzumab, Polatuzumab vedotin, DCDS4501S, RG7596, Rituximab, Rituxan, Doxorubicin Hydrochloride, Hydroxydaunomycin, Cyclophosphamide, Cytophosphane, Cytoxan, Prednisone, Prednisolone, Methylprednisolone
Jennifer Crombie, MD, Genentech, Inc.
Lymphoma, Lymphoma, Large B-Cell, Diffuse
09/26
09/29
NCT05410418: Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

Recruiting
2
34
US
Mosunetuzumab, RO7030816, BTCT4465A, Polatuzumab vedotin, RO5541077, DCDS4501A
Washington University School of Medicine, Genentech, Inc., Institute for Follicular Lymphoma
Lymphoma, Follicular, Follicular Lymphoma
10/26
10/31
NCT04659044: Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Terminated
2
3
US
Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma
03/24
03/24
NCT05868395: Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Recruiting
2
16
Europe
Polatuzumab, bendamustin und rituximab, Polivy, Bendamustin, Mabthera
Medical University of Vienna
Mantle-cell Lymphoma
05/27
05/27
R-Pola-Glo, NCT05798156: Rituximab in Combination with Glofitamab and Polatuzumab Vedotin in Patients with Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Recruiting
2
125
Europe
Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse
04/25
09/28
NCT06043674: A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation

Recruiting
2
66
US
Glofitamab, RO7082859, Obinutuzumab, RO5072759, GA101, GAZYVA, GAZYVARO, Polatuzumab Vedotin, Atezolizumab, Tecentriq, Tocilizumab, Actemra
Christine Ryan, Genentech, Inc.
Chronic Lymphocytic Leukemia, Richter's Transformation
01/28
01/33
RADICAL, NCT05253495: Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

Recruiting
2
80
US
DOC Group B, Reduction Phase, Pv-COMRAD 1 and 2 Group B, Induction 1 and 2, Pv-R-CYM 1 and 2 Group B, Consolidation 1 and 2, DOC Group C, Reduction with IT, MAD CPR 1 and 2, Induction 1 and 2 Group C, Pv-R CYVE 1 and 2, Consolidation 1 and 2 Group C CNS Negative, Pv-R CYVE-MTX 1 and 2, Consolidation 1 and 2 Group C CNS Positive, MAD CP, Maintenance 1 Group C, Pv-Cytarabine/etoposide, Maintenance 2, 4 Group C, AD CP, Maintenance 3 Group C, Bv-AVD-R 1 and 2: COHORT IIa, Intermediate Risk cohort IIa, Bv-NVD-R, Cycle 1-2, Cohort IIa Rapid Early Responders, Bv-NVD-R, Cycle 1-4 SER, Cohort IIa Slow Early Responders, Bv-AVD-R, High-Risk cohort IIb, Bv-NVD-R, Cycle 1-4 RER, cohort IIb Rapid Early Responders, Bv-NAVD-R, Cycle 1-2, cohort IIb Slow Early Responders, Involved Site Radiation Therapy, Cohort II ONLY
New York Medical College
Non-hodgkin Lymphoma, Hodgkin Lymphoma
12/27
06/28
PORTAL, NCT06071871: A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

Recruiting
2
99
Europe
Glofitamab, Columvi, Polatuzumab vedotin, Polivy, Obinutuzumab, Gazyvaro
University College, London, Hoffmann-La Roche
Large B-cell Lymphoma
07/27
07/28
NCT05498220: Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
44
US
Polatuzumab vedotin (PV), Rituximab, Hyaluronidase, Gemcitabine, Cisplatin, Dexamethasone, GCSF
UNC Lineberger Comprehensive Cancer Center, Genentech, Inc.
Diffuse Large B-cell Lymphoma
08/28
08/28
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn
2
150
Europe
R-DHAP, Pola-R-DHAP
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
01/29
01/29
EPCORE NHL-5, NCT05283720 / 2021-005725-24: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Recruiting
2
622
Europe, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013;, Lenalidomide, Ibrutinib, Imbruvica, Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride [HCl], Prednisone, Polatuzumab Vedotin, Venetoclax, Venclexta;, ABT-199, GDC-0199, CC-99282, Pirtobrutinib
Genmab, AbbVie
Non-Hodgkin Lymphoma
11/32
11/32
GO40554, NCT03677154 / 2018-001127-40: Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Checkmark First-patient-in for cohort C of P1 trial for 1L elderly/unfit DLBCL
Feb 2021 - Feb 2021: First-patient-in for cohort C of P1 trial for 1L elderly/unfit DLBCL
Checkmark Data from trial for elderly/unfit 1L DLBCL at ASH 2020
Dec 2020 - Dec 2020: Data from trial for elderly/unfit 1L DLBCL at ASH 2020
Active, not recruiting
1/2
188
Europe, US, RoW
Mosunetuzumab Intravenous (IV), Mosunetuzumab Subcutaneous (SC), Polatuzumab Vedotin, Tocilizumab
Hoffmann-La Roche
Diffuse Large B-cell Lymphoma
08/25
08/25
GO40515, NCT03677141 / 2018-001039-29: A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Checkmark Data from trial in combination with CHOP for 1L DLBCL at ASH 2020
Dec 2020 - Dec 2020: Data from trial in combination with CHOP for 1L DLBCL at ASH 2020
Completed
1/2
117
Europe, US, RoW
Mosunetuzumab, Polatuzumab Vedotin, Rituxumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tocilizumab
Hoffmann-La Roche
B-cell Non-Hodgkin Lymphoma
10/23
10/23
COALITION, NCT04914741: A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

Active, not recruiting
1/2
80
RoW
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Glofitamab, RO7082859, CD20-TCB, Polatuzumab vedotin
Peter MacCallum Cancer Centre, Australia, Hoffmann-La Roche
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
12/23
07/25
NCT04491370: Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

Recruiting
1/2
20
US
Polatuzumab vedotin
New York Medical College
B-cell Lymphoma, Burkitt Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Transformed Non-Hodgkin Lymphoma, Richter Syndrome, Hodgkin Lymphoma
08/24
08/25
GO40516, NCT03671018 / 2018-001141-13: A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

Checkmark Data from trial in combination with polatuzumab vedotin for DLBCL at ASH 2021
Dec 2021 - Dec 2021: Data from trial in combination with polatuzumab vedotin for DLBCL at ASH 2021
Checkmark Data from trial in combination with polivy for r/r NHL
Jun 2021 - Jun 2021: Data from trial in combination with polivy for r/r NHL
Checkmark Preliminary data from trial in combination with Polivy for NHL at ASH 2020
More
Active, not recruiting
1/2
422
Europe, Canada, US
Mosunetuzumab (IV), BTCT4465A, Mosunetuzumab (SC), Polatuzumab vedotin, Tocilizumab, Rituximab
Hoffmann-La Roche
B-cell Non-Hodgkin Lymphoma
01/24
07/25
NP39488, NCT03533283: An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Active, not recruiting
1/2
211
Europe, RoW
Glofitamab, RO7082859, Columvi, Atezolizumab, Obinutuzumab, Tocilizumab, Actemra, Polatuzumab Vedotin, 89Zr-Df-IAB22M2C
Hoffmann-La Roche
Non-Hodgkins Lymphoma
09/26
09/26
NCT05455697: Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Recruiting
1/2
35
US
Bone Marrow Biopsy, Cyclophosphamide, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cyclostine, Cytophosphane, Cytoxan, Fosfaseron, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, 14-Hydroxydaunomycin, 23214-92-8, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Prednisone, Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltra, Econosone, Lisacort, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Predicor, Predicorten, Prednicort, Prednilonga, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Retifanlimab, 2226345-85-1, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human, Tafasitamab, 1422527-84-1, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain,, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574, Vincristine, 22-Oxovincaleukoblastine, 57-22-7, LEUROCRISTINE, VCR, Vincrystine, Bone Marrow Aspiration, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Fludeoxyglucose F-18, 105851-17-0, 18FDG, Positron Emission Tomography, Medical Imaging, PET Scan, Positron Emission Tomography Scan, Computed Tomography, CAT Scan, Computed Axial Tomography, CT SCAN, Biospecimen Collection, Biological Sample Collection, Polatuzumab Vedotin, Antibody-Drug Conjugate DCDS4501A, Polivy
University of Washington
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
01/26
07/26
NCT06040320: Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

Recruiting
1/2
12
US
Polatuzumab vedotin, Polivy, Rituximab, Rituxan, CHP
Washington University School of Medicine
Post-transplant Lymphoproliferative Disorder
05/26
05/31
JapicCTI-142580: Phase I Study of RO5541077 in Patients with B cell Non-Hodgkin s Lymphoma

Completed
1
18
Japan
Polivy (polatuzumab vedotin-piiq) - Roche
Chugai Pharmaceutical Co., Ltd.
B cell Non-Hodgkin s Lymphoma
 
 
BO42203, NCT04790903: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated
1
50
Europe, US
Venetoclax, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse
05/24
05/24
CC-220-DLBCL-001, NCT04884035: Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Recruiting
1
174
Europe, US, RoW
CC-220, Iberdomide, BMS-986382, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Prednisolone, CC-99282, BMS-986369, Polatuzumab vedotin
Celgene
Lymphoma, B-Cell
06/27
06/27
NCT04739813: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Recruiting
1
55
US
obinutuzumab, prednisone, Revlimid, Polatuzumab, ibrutinib, venetoclax
National Cancer Institute (NCI)
Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
10/25
10/30
NP40126, NCT03467373: A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Checkmark Safety and efficacy of phase 1 study in combination with R-CHOP in patients with previously untreated DLBCL
Dec 2022 - Dec 2022: Safety and efficacy of phase 1 study in combination with R-CHOP in patients with previously untreated DLBCL
Completed
1
111
Europe, Canada, US, RoW
Glofitamab, RO7082859, Obinutuzumab (G), Gazyva, Rituximab (R), Rituxan, Tocilizumab, Actemra, Cyclophosphamide, Doxorubicin, Vincristine, Oncovin, Prednisone, Polatuzumab vedotin
Hoffmann-La Roche
B-Cell Lymphoma, Non-Hodgkin Lymphoma
12/24
12/24
LOTIS 7, NCT04970901: A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Recruiting
1
200
Europe, US, RoW
Loncastuximab Tesirine, ZYNLONTA, ADCT-402, Polatuzumab Vedotin, Glofitamab, Mosunetuzumab, Obinutuzumab
ADC Therapeutics S.A.
B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
12/25
12/26
NCT06730542: Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in Patients with Secondary CNS Lymphoma

Recruiting
1
20
US
Zanubrutinib, Methotrexate, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
Juan P. Alderuccio, MD, BeiGene
CNS Lymphoma
03/30
03/30
NCT06015880: Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
1
30
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, FCU-2711, FCU2711, polatuzumab vedotin-piiq, Polivy, RG 7596, RG-7596, RG7596, Ro 5541077-000, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT
National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
06/26
06/26
NCT04323956: Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Active, not recruiting
1
50
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Asta B 518, B-518, WR-138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Parsaclisib, (4R)-4-(3-((1S)-1-(4-Amino-3-methyl-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, IBI376, INCB 50465, INCB-50465, INCB050465, INCB50465, WHO 10589, Pegfilgrastim, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, pegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv, Pegfilgrastim-jmdb, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Udenyca, Ziextenzo, Neupopeg, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Ikgdar, Mabtas, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Mayo Clinic, National Cancer Institute (NCI)
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Indolent Non-Hodgkin Lymphoma
05/26
05/27
NCT04231877: Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Recruiting
1
56
US
Polatuzumab Vedotin, 1313206-42-6, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Rituximab, 174722-31-7, 687451, ABP 798, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, IDEC-C2B8 Monoclonal Antibody, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, rituximab-abbs, Rituximab Biosimilar SIBP-02, Riabni, Rituximab ARRX, Rituximab PVVR, Ruxience, Prednisone, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Metacortandracin, Meticorten, Ofisolona, Panafcort, Paracort, Predicor, Predicorten, Prednidib, Prednilonga, Prednitone, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Cyclophosphamide, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Glofitamab, Glofitamab-gxbm, RO7082859, Multigated Acquisition Scan, MUGA Scan, MUGA, Echocardiography, EC, FDG-Positron Emission Tomography, FDG-PET, FDG-PET Imaging, Computed Tomography, CAT Scan, CT Scan, Computed Axial Tomography, Bone Marrow Biopsy, Biospecimen Collection, Bone Marrow Aspiration
University of Washington, Genentech, Inc.
Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Gray-Zone Lymphoma
12/26
12/31
POLASTAR, jRCT1071220082: Polatuzumab vedotin plus R-CHP therapy in patients with previously untreated diffuse large B-cell lymphoma

Active, not recruiting
N/A
500
Japan
Polivy (polatuzumab vedotin-piiq) - Roche, Rituxan (rituximab) - Roche, cyclophosphamide - Generic mfg., doxorubicin hydrochloride - Generic mfg., prednisone - Generic mfg.
Kyushu University Hospital, Chugai Pharmaceutical Co., Ltd.
Diffuse large B-cell lymphoma
 
 
POSS, NCT06734078: An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated with Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme

Active, not recruiting
N/A
100
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
DLBCL - Diffuse Large B Cell Lymphoma
12/25
12/25
APOLLO, ISRCTN11542980: Evaluating alternative treatment regimens for patients who have diffuse large B-cell lymphoma that is unsuitable for standard treatment

No Longer Available
N/A
56
United Kingdom, England, Scotland
Polivy (polatuzumab vedotin-piiq) - Roche
Clatterbridge Cancer Centre NHS Foundation Trust, Roche;Hoffman-La Roche
Diffuse large B-cell lymphoma
 
 
UMIN000053834: A database study on the occurrence of febrile neutropenia and other symptoms and prophylactic treatment in untreated diffuse large B-cell lymphoma, including patients aged 80 years or older

Not yet recruiting
N/A
1000
Japan
Polivy (polatuzumab vedotin-piiq) - Roche, cyclophosphamide - Generic mfg., doxorubicin hydrochloride - Generic mfg.
Chugai Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd.
Diffuse large B-cell lymphoma;Large B-Cell Lymphoma
 
 
NCT05954910: A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma

Recruiting
N/A
1000
RoW
Polatuzumab Vedotin, POLIVY ®
Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma
05/27
05/27
ChiCTR2400082122: A single-center, observational study of polatuzumab vedotin-based regimen for older patients with relapsed/refractory diffuse large B-cell lymphoma

Not yet recruiting
N/A
47
 
None; None
Beijing Hospital; Beijing Hospital, Self funding
Diffuse large B cell lymphoma
 
 
NCT04624893: A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin

Recruiting
N/A
35
RoW
Polatuzumab Vedotin-Piiq, Polatuzumab Vedotin
Jiangsu Cancer Institute & Hospital
Diffuse Large B-Cell Lymphoma (DLBCL)
12/20
12/20
SHR-A1912 / Jiangsu Hengrui Pharma
SHR-A1912-II-201, NCT06104553: A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma

Recruiting
1/2
132
RoW
SHR-A1912; R-Chemo
Shanghai Hengrui Pharmaceutical Co., Ltd.
B-cell Non-Hodgkin's Lymphoma
12/25
06/26
SHR-A1912-I-101, NCT05113069: A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas

Enrolling by invitation
1
170
RoW
SHR-A1912
Shanghai Hengrui Pharmaceutical Co., Ltd.
B Cell Lymphoma
03/24
03/25
SHR-A1904-301, NCT06350006: SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor

Recruiting
1
924
RoW
SHR-A1904; Adebrelimab, SHR-A1904; CAPOX; Adebrelimab
Shanghai Hengrui Pharmaceutical Co., Ltd.
Cldn18.2-positive Advanced Solid Tumor
12/27
12/28
ARC-02 / Araris Biotech
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Polivy (polatuzumab vedotin-piiq) / Roche
ChiCTR2300077262: A single-arm, multicenter, exploratory study of Polatuzumab Vedotin for injection in combination with Rituximab, Cyclophosphamide, Pirarubicin, and Prednisone in the initial treatment of diffuse large B-cell lymphoma

Recruiting
4
76
 
Polatuzumab Vedotin for Injection 1.8mg/kg, d0Rituximab 375mg/m2, d0Cyclophosphamide 750mg/m2, d1Pirarubicin 50mg/m2, d1Prednisone 100mg, d1-5
Shanxi Cancer Hospital; Shanxi Cancer Hospital, Shanxi Society of Geriatrics
Diffuse large B lymphoma
 
 
2019-002962-10: An unblinded study to compare the treatment success and tolerability of a chemotherapy consisting of a combination of rituximab, ifosfamide, carboplatin and etoposide with and without the addition of polatuzumab vedotin in subject suffering from an aggressive lymphoma, a malignant disease of the lymphatic system.

Not yet recruiting
3
334
Europe
Polivy, Mabthera, Ifosfamide, Carboplatin, Etoposide, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for injection/infusion, Polivy, MABTHERA®
GWT-TUD GmbH, F. Hoffmann-La Roche Ltd
primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), patients whose cancer of the lymph nodes has returned or not responded to treatment, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
POLARIX, NCT03274492 / 2017-002023-21: A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

Hourglass Apr 2023 - Apr 2023 : Anticipated approval in combination with Rituxan plus cyclophosphamide, doxorubicin & prednisone for 1L DLBCL based on POLARIX trial
Hourglass Apr 2022 - Dec 2022 : Submission in US for 1L DLBCL
Checkmark Updated data from POLARIX trial for 1L DLBCL at ASH 2022
Dec 2022 - Dec 2022: Updated data from POLARIX trial for 1L DLBCL at ASH 2022
Checkmark Presentation of POLARIX trial in 1L DLBCL at ASH 2022
More
Active, not recruiting
3
1000
Europe, Canada, Japan, US, RoW
Polatuzumab Vedotin, DCDS4501A; anti-CD79b-VC-MMAE, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Vincristine Placebo, Prednisone, Polatuzumab vedotin Placebo
Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma
07/26
07/26
POTENT, NCT06522555: The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma

Recruiting
3
100
RoW
polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide, zanubrutinib, rituximab and lenalidomide
Ruijin Hospital
Diffuse Large B-Cell Lymphoma
08/28
08/29
POLARGO, NCT04182204 / 2018-003727-10: A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting
3
270
Europe, Canada, US, RoW
Polatuzumab Vedotin, Rituximab, Mabthera; Rituxan, Gemcitabine, Oxaliplatin
Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma
11/24
03/25
Pola-R-ICE, NCT04833114 / 2019-002962-10: Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide () Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Active, not recruiting
3
306
Europe
Polatuzumab Vedotin, Mabthera, Ifosfamide, Carboplatin, Etoposide
GWT-TUD GmbH, Hoffmann-La Roche
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
12/26
12/27
SUNMO, NCT05171647: A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Calendar Jan 2025 - Dec 2026: Submission in US in combination with Lunsumio for 2L DLBCL
Jan 2023 - Dec 2024: Data from SUNMO trial in combination with polivy for 2L+ DLBCL
Active, not recruiting
3
242
Canada, Japan, US, RoW
Mosunetuzumab, Polatuzumab vedotin, Tocilizumab, Rituximab, Gemcitabine, Oxaliplatin
Hoffmann-La Roche
Non-Hodgkin Lymphoma
05/25
02/27
SKYGLO, NCT06047080: An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Recruiting
3
1130
Europe, Canada, Japan, US, RoW
Glofitamab, Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
Hoffmann-La Roche
Large B-Cell Lymphoma
06/26
02/29
jRCT2080223990: A phase II Study of Polatuzumab Vedotin in Combination with Rituximab plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Completed
2
35
Japan
Polivy (polatuzumab vedotin-piiq) - Roche, bendamustine - Generic mfg., Rituxan (rituximab) - Roche
CHUGAI PHARMACEUTICAL CO., LTD.
B cell Non-Hodgkin Lymphoma
 
 
2019-000842-36: Polatuzumab vedotin combined with standard chemo-immunotherapy drugs in diffuse large B-cell lymphoma

Not yet recruiting
2
56
Europe
Polatuzumab Vedotin, Lyophilisate for solution for infusion
The Clatterbridge Cancer Centre NHS Foundation Trust, Roche Products Ltd
Diffuse large B-cell lymphoma in patients with co-morbidities who cannot tolerate full dose R-CHOP., A cancer of the blood affecting B-cells., Diseases [C] - Cancer [C04]
 
 
2021-000468-32: Study for patients with mantle cell lymphoma (one type of lymphomas = lymph node cancer), aimed to answer the question if patients who relapse after previous therapy with Bruton tyrosine kinase inhibitor (type of biologivcal treatment) will be beneficiary adding of polatuzumab vedotin (new type of biological treatment) to commonly used treatment with bendamustine and rituxima (combination of chemotherpay and biological treatment) Studie pro pacienty s lymfomem z plášťových buněk (jeden z podtypů lymfomu), která se snaží odpovědět na otázku, zda u pacientů, u kterých selhala předchozí léčba inhibitory Brutonovy kinázy (typ biologické léčby), bude přinosem přidání polatuzumab vedotinu (nový typ biologické léčby) k již běžně používané záchranné léčbě (kombinace bendamustinu a rituximabu (tj. chemoterapie a biologické léčby)

Not yet recruiting
2
21
RoW
Polatuzumab vedotin, Bendamustine Accord 25 mg/ml, Mabthera, RO5541077, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Polivy, Bendamustine Accord, Mabthera
Kooperativní lymfomová skupina, z.s., Kooperativní lymfomová skupina, z.s.
Mantle cell lymphoma lymfom z plášťových buněk, aggressive lymph node cancer of B-cell origin agresivní nádorové onemocnění z mízních uzlin z B-buněk, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2021-006030-40: EFFICACY OF POLATUZUMAB, BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MANTLE CELL LYMPHOMA

Not yet recruiting
2
16
Europe
Powder for solution for infusion, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Polivy, Bendamustin Accord, MabThera
Med. Univ. Wien, Klinik f. Innere Med I, Onkologie
MANTLE CELL LYMPHOMA, MANTLE CELL LYMPHOMA, Diseases [C] - Cancer [C04]
 
 
2022-003398-51: A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dose R-CHOP Eine prospektive, multizentrische Phase-2-Studie zur chemotherapiearmen Kombination von Rituximab mit dem Antikörper-Wirkstoff-Konjugat Polatuzumab Vedotin und dem bispezifischen Antikörper Glofitamab bei zuvor unbehandelten Patienten mit aggressivem B-Zell-Lymphom über 60 Jahren, die für ein voll dosiertes R-CHOP nicht in Frage kommen

Not yet recruiting
2
80
Europe
Glofitamab, Obinutuzumab, Polatuzumab vedotin, Rituximab, RO7082859, RO5072759, RO5541077, RO0452294, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Columvi, GAZYVARO, Polivy, MabThera
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Roche Pharma AG, Roche Austria GmbH
aggressive large B-cell lymphoma, aggressive large B-cell lymphoma, Diseases [C] - Cancer [C04]
 
 
NCT06468943: Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Enrolling by invitation
2
20
RoW
Polatuzumab Vedotin, Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
The First Affiliated Hospital of Soochow University
Effects of Chemotherapy, Safety Issues
05/26
05/28
2022-PUMCH-A-194, NCT06176729: Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

Recruiting
2
30
RoW
Polatuzumab Vedotin, Rituximab, Lenalidomide
Yan Zhang, MD, Peking University Third Hospital, Peking University First Hospital, Chinese PLA General Hospital
Diffuse Large B Cell Lymphoma
10/25
10/27
NCT04479267: Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

Recruiting
2
49
US
Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione, 53-03-2, Adasone, Cortancyl, Dacortin, , Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Prednisolone, (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, .delta.1-Hydrocortisone, 1,2-Dehydrohydrocortisone, 50-24-8, 9120, Adnisolone, Aprednislon, Capsoid, Cortalone, Cortisolone, Methylprednisolone, (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione, 6Alpha-Methylprednisolone, Adlone, Caberdelta M, DepMedalone, Depo Moderin, Depo-Nisolone, Duralone, Emmetipi, Esametone, Rituximab, 174722-31-7, 687451, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, Polatuzumab Vedotin, 1313206-42-6, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, POLATUZUMAB VEDOTIN, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Cyclophosphamide, 1-bis(2-chloroethyl)-amino-1-oxo-2-aza-5-oxaphosphoridin monohydrate, 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, Doxorubicin Hydrochloride, 14-Hydroxydaunorubicin Hydrochloride, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements, Double Expressor Lymphoma, High-grade B-cell Lymphoma
11/25
11/26
NCT04665765: Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting
2
41
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
City of Hope Medical Center, National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma Unclassifiable, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
07/22
07/25
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
01/25
07/29
NCT04594798: A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients with DLBCL

Recruiting
2
39
US
Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
University of Rochester, Genentech, Inc.
DLBCL, Lymphoma, B-Cell
07/26
07/26
NCI-2021-12489, NCT05169658: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Active, not recruiting
2
42
US
Mosunetuzumab, 1905409-39-3, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, RG 7828, RG-7828, RG7828, RO7030816, Lunsumio, Mosunetuzumab-axgb, Obinutuzumab, 949142-50-1, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Polatuzumab Vedotin, 1313206-42-6, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, FDG-Positron Emission Tomography, FDG-PET, FDG-PET Imaging, Computed Tomography, CT Scan, CAT Scan, Computed Axial Tomography, Positron Emission Tomography, PET scan, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, Biological Sample Collection
University of Washington, Genentech, Inc.
Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
03/25
03/25
NCT06530511: Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL

Recruiting
2
30
RoW
Polatuzumab vedotin, Rituximab, Orelabrutinib
Affiliated Hospital of Nantong University
Diffuse Large B Cell Lymphoma
02/26
08/26
NCT06554600: A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
36
RoW
Zanubrutinib, Polatuzumab Vedotin, Bendamustine, Rituximab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Refractory or Relapsed Diffuse Large B Cell Lymphoma
08/26
08/28
NCT06453044: Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed or Refractory Grade 1-3a Follicular Lymphoma

Recruiting
2
41
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Questionnaire Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma
03/28
03/28
2024-SR-436, NCT06516978: A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Not yet recruiting
2
528
NA
Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Orelabrutinib, Venetoclax, Chidamide, Penpulimab, Lenalidomide
The First Affiliated Hospital with Nanjing Medical University
Diffuse Large B Cell Lymphoma
10/28
04/29
NCT06664411: Pola-ZR2P in Previously Untreated DLBCL

Not yet recruiting
2
80
RoW
Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy, Pola-ZR2P
Navy General Hospital, Beijing
Diffuse Large B-cell Lymphoma
12/29
12/30
NCT05633615: Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
396
US
Axicabtagene Ciloleucel, KTE C19, KTE-C19, KTE-C19 CAR, Yescarta, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Lisocabtagene Maraleucel, Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017, Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017, Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017, Breyanzi, JCAR 017, JCAR017, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, RG 7828, RG-7828, RG7828, RO7030816, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tisagenlecleucel, CART-19, CART19, CTL019, CTL019 T-cells, Kymriah, Tisagenlecleucel-T
SWOG Cancer Research Network, National Cancer Institute (NCI), Genentech, Inc.
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
12/25
12/29
GUIDANCE-005, NCT06441097: Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Not yet recruiting
2
152
NA
Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone, Acalabrutinib, Lenalidomide, Decitabine
Ruijin Hospital
Diffuse Large B-Cell Lymphoma
12/27
12/27
NCT06665217: G-Pola-ZLP in Diffuse Large B-Cell Lymphoma

Not yet recruiting
2
80
NA
Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy, G-Pola-ZLP
Navy General Hospital, Beijing
Diffuse Large B-Cell Lymphoma
01/29
01/30
GLORY, NCT06765317: A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

Recruiting
2
42
US
Glofitamab, Polatuzumab, Rituximab, Cyclophosphamide, Doxorubicin, Obinutuzumab:
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma
01/28
01/28
NCT06743945: POLA-R-CHP in the First-line Treatment of Transformed DLBCL

Recruiting
2
20
RoW
POLA-R-CHP, polatuzumab vedotin and R-CHP
Fudan University
Transformed Lymphoma
12/27
12/29
GUIDANCE05, NCT06803693: Efficacy and Safety of Pola-RCHP-X Vs Pola-RCHP in Untreated DLBCL

Not yet recruiting
2
152
NA
Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone, Zanubrutinib, Lenalidomide, Decitabine
Ruijin Hospital
Diffuse Large B-Cell Lymphoma
04/28
12/28
NCT06890884: A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBL) (MK-2140-011/waveLINE-011)

Not yet recruiting
2
594
NA
Zilovertamab vedotin, MK-2140, VLS-101, Rituximab, RITUXAN®, Cyclophosphamide, CYTOXAN®, NEOSAR®, Doxorubicin, ADRIAMYCIN®, Rituximab Biosimilar, TRUXIMA®, RUXIENCE®, RIABNI®, Prednisone, Prednisolone, Polatuzumab vedotin
Merck Sharp & Dohme LLC
Lymphoma, Large B-Cell, Diffuse
12/27
12/32
NCT06594939: Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Not yet recruiting
2
31
US
Polatuzumab Vedotin, Polivy, Mosunetuzumab, Lunsumio, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Prednisone, Pegfilgrastim, filgrastim
Medical College of Wisconsin
Diffuse Large B Cell Lymphoma (DLBCL)
06/28
12/29
NCT05940051: Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
35
RoW
Zanubrutinib, Polatuzumab vedotin and Rituximab
Peng Liu
Diffuse Large B Cell Lymphoma
07/25
12/25
SHZS-DLBCL003, NCT05940064: Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma

Recruiting
2
30
RoW
Zanubrutinib, Polatuzumab Vedotin, Rituximab, ZPR
Peng Liu
Diffuse Large B Cell Lymphoma
07/25
12/25
NCT05615636: A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Recruiting
2
36
US
Mosunetuzumab, RO7030816, Polatuzumab vedotin, Tafasitamab, Lenalidomide, CC-5013, Revlimid
M.D. Anderson Cancer Center
Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL
08/25
08/27
NCT04679012: Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Recruiting
2
20
US
Polatuzumab Vedotin, Polivy, Rituximab, Rituxan, chimeric anti-CD20 monoclonal antibody, Etoposide, VP-16, VePesid, etopophos, toposar, Prednisone, Deltasone, Orasone, Paracort, Cortan, Cyclophosphamide, cytoxan, Hydroxydaunomycin, Doxorubicin Hydrochloride, Hydroxydoxorubicin Hydrochloride
Weill Medical College of Cornell University, Genentech, Inc.
Richter Syndrome, Chronic Lymphocytic Leukemia
09/25
09/26
GRAIL, NCT06050694: Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL

Not yet recruiting
2
40
Canada
glofitamab
University Health Network, Toronto
Diffuse Large B Cell Lymphoma (DLBCL)
11/25
11/27
NCT05260957: CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

Recruiting
2
22
US
Mosunetuzumab, BTCT4465A, Polatuzumab, Polatuzumab Vedotin, RO5541077, Polivy, CAR-T Cell Therapy, Chimeric antigen receptor T-Cell Therapy
Lazaros Lekakis, Genentech, Inc.
Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma
12/25
12/27
CLSGMCLPOLA, NCT04913103: Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL

Not yet recruiting
2
21
RoW
Polatuzumab vedotin, Polivy, Bendamustine Hydrochloride, Bendamustine Accord, Bendamustine Glenmark, Bendamustine KABI, Rituximab, Mabthera, Rixathon, Truxima
Czech Lymphoma Study Group
Lymphoma, Mantle-Cell
08/26
08/27
NCT05800366: A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients with High-risk Diffuse Large B-cell Lymphoma

Active, not recruiting
2
41
US
Glofitamab, RO7082859, Polatuzumab, Polatuzumab vedotin, DCDS4501S, RG7596, Rituximab, Rituxan, Doxorubicin Hydrochloride, Hydroxydaunomycin, Cyclophosphamide, Cytophosphane, Cytoxan, Prednisone, Prednisolone, Methylprednisolone
Jennifer Crombie, MD, Genentech, Inc.
Lymphoma, Lymphoma, Large B-Cell, Diffuse
09/26
09/29
NCT05410418: Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

Recruiting
2
34
US
Mosunetuzumab, RO7030816, BTCT4465A, Polatuzumab vedotin, RO5541077, DCDS4501A
Washington University School of Medicine, Genentech, Inc., Institute for Follicular Lymphoma
Lymphoma, Follicular, Follicular Lymphoma
10/26
10/31
NCT04659044: Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Terminated
2
3
US
Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma
03/24
03/24
NCT05868395: Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Recruiting
2
16
Europe
Polatuzumab, bendamustin und rituximab, Polivy, Bendamustin, Mabthera
Medical University of Vienna
Mantle-cell Lymphoma
05/27
05/27
R-Pola-Glo, NCT05798156: Rituximab in Combination with Glofitamab and Polatuzumab Vedotin in Patients with Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Recruiting
2
125
Europe
Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse
04/25
09/28
NCT06043674: A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation

Recruiting
2
66
US
Glofitamab, RO7082859, Obinutuzumab, RO5072759, GA101, GAZYVA, GAZYVARO, Polatuzumab Vedotin, Atezolizumab, Tecentriq, Tocilizumab, Actemra
Christine Ryan, Genentech, Inc.
Chronic Lymphocytic Leukemia, Richter's Transformation
01/28
01/33
RADICAL, NCT05253495: Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

Recruiting
2
80
US
DOC Group B, Reduction Phase, Pv-COMRAD 1 and 2 Group B, Induction 1 and 2, Pv-R-CYM 1 and 2 Group B, Consolidation 1 and 2, DOC Group C, Reduction with IT, MAD CPR 1 and 2, Induction 1 and 2 Group C, Pv-R CYVE 1 and 2, Consolidation 1 and 2 Group C CNS Negative, Pv-R CYVE-MTX 1 and 2, Consolidation 1 and 2 Group C CNS Positive, MAD CP, Maintenance 1 Group C, Pv-Cytarabine/etoposide, Maintenance 2, 4 Group C, AD CP, Maintenance 3 Group C, Bv-AVD-R 1 and 2: COHORT IIa, Intermediate Risk cohort IIa, Bv-NVD-R, Cycle 1-2, Cohort IIa Rapid Early Responders, Bv-NVD-R, Cycle 1-4 SER, Cohort IIa Slow Early Responders, Bv-AVD-R, High-Risk cohort IIb, Bv-NVD-R, Cycle 1-4 RER, cohort IIb Rapid Early Responders, Bv-NAVD-R, Cycle 1-2, cohort IIb Slow Early Responders, Involved Site Radiation Therapy, Cohort II ONLY
New York Medical College
Non-hodgkin Lymphoma, Hodgkin Lymphoma
12/27
06/28
PORTAL, NCT06071871: A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

Recruiting
2
99
Europe
Glofitamab, Columvi, Polatuzumab vedotin, Polivy, Obinutuzumab, Gazyvaro
University College, London, Hoffmann-La Roche
Large B-cell Lymphoma
07/27
07/28
NCT05498220: Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
44
US
Polatuzumab vedotin (PV), Rituximab, Hyaluronidase, Gemcitabine, Cisplatin, Dexamethasone, GCSF
UNC Lineberger Comprehensive Cancer Center, Genentech, Inc.
Diffuse Large B-cell Lymphoma
08/28
08/28
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn
2
150
Europe
R-DHAP, Pola-R-DHAP
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
01/29
01/29
EPCORE NHL-5, NCT05283720 / 2021-005725-24: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Recruiting
2
622
Europe, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013;, Lenalidomide, Ibrutinib, Imbruvica, Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride [HCl], Prednisone, Polatuzumab Vedotin, Venetoclax, Venclexta;, ABT-199, GDC-0199, CC-99282, Pirtobrutinib
Genmab, AbbVie
Non-Hodgkin Lymphoma
11/32
11/32
GO40554, NCT03677154 / 2018-001127-40: Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Checkmark First-patient-in for cohort C of P1 trial for 1L elderly/unfit DLBCL
Feb 2021 - Feb 2021: First-patient-in for cohort C of P1 trial for 1L elderly/unfit DLBCL
Checkmark Data from trial for elderly/unfit 1L DLBCL at ASH 2020
Dec 2020 - Dec 2020: Data from trial for elderly/unfit 1L DLBCL at ASH 2020
Active, not recruiting
1/2
188
Europe, US, RoW
Mosunetuzumab Intravenous (IV), Mosunetuzumab Subcutaneous (SC), Polatuzumab Vedotin, Tocilizumab
Hoffmann-La Roche
Diffuse Large B-cell Lymphoma
08/25
08/25
GO40515, NCT03677141 / 2018-001039-29: A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Checkmark Data from trial in combination with CHOP for 1L DLBCL at ASH 2020
Dec 2020 - Dec 2020: Data from trial in combination with CHOP for 1L DLBCL at ASH 2020
Completed
1/2
117
Europe, US, RoW
Mosunetuzumab, Polatuzumab Vedotin, Rituxumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tocilizumab
Hoffmann-La Roche
B-cell Non-Hodgkin Lymphoma
10/23
10/23
COALITION, NCT04914741: A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

Active, not recruiting
1/2
80
RoW
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Glofitamab, RO7082859, CD20-TCB, Polatuzumab vedotin
Peter MacCallum Cancer Centre, Australia, Hoffmann-La Roche
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
12/23
07/25
NCT04491370: Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

Recruiting
1/2
20
US
Polatuzumab vedotin
New York Medical College
B-cell Lymphoma, Burkitt Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Transformed Non-Hodgkin Lymphoma, Richter Syndrome, Hodgkin Lymphoma
08/24
08/25
GO40516, NCT03671018 / 2018-001141-13: A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

Checkmark Data from trial in combination with polatuzumab vedotin for DLBCL at ASH 2021
Dec 2021 - Dec 2021: Data from trial in combination with polatuzumab vedotin for DLBCL at ASH 2021
Checkmark Data from trial in combination with polivy for r/r NHL
Jun 2021 - Jun 2021: Data from trial in combination with polivy for r/r NHL
Checkmark Preliminary data from trial in combination with Polivy for NHL at ASH 2020
More
Active, not recruiting
1/2
422
Europe, Canada, US
Mosunetuzumab (IV), BTCT4465A, Mosunetuzumab (SC), Polatuzumab vedotin, Tocilizumab, Rituximab
Hoffmann-La Roche
B-cell Non-Hodgkin Lymphoma
01/24
07/25
NP39488, NCT03533283: An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Active, not recruiting
1/2
211
Europe, RoW
Glofitamab, RO7082859, Columvi, Atezolizumab, Obinutuzumab, Tocilizumab, Actemra, Polatuzumab Vedotin, 89Zr-Df-IAB22M2C
Hoffmann-La Roche
Non-Hodgkins Lymphoma
09/26
09/26
NCT05455697: Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Recruiting
1/2
35
US
Bone Marrow Biopsy, Cyclophosphamide, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cyclostine, Cytophosphane, Cytoxan, Fosfaseron, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, 14-Hydroxydaunomycin, 23214-92-8, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Prednisone, Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltra, Econosone, Lisacort, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Predicor, Predicorten, Prednicort, Prednilonga, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Retifanlimab, 2226345-85-1, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human, Tafasitamab, 1422527-84-1, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain,, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574, Vincristine, 22-Oxovincaleukoblastine, 57-22-7, LEUROCRISTINE, VCR, Vincrystine, Bone Marrow Aspiration, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Fludeoxyglucose F-18, 105851-17-0, 18FDG, Positron Emission Tomography, Medical Imaging, PET Scan, Positron Emission Tomography Scan, Computed Tomography, CAT Scan, Computed Axial Tomography, CT SCAN, Biospecimen Collection, Biological Sample Collection, Polatuzumab Vedotin, Antibody-Drug Conjugate DCDS4501A, Polivy
University of Washington
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
01/26
07/26
NCT06040320: Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

Recruiting
1/2
12
US
Polatuzumab vedotin, Polivy, Rituximab, Rituxan, CHP
Washington University School of Medicine
Post-transplant Lymphoproliferative Disorder
05/26
05/31
JapicCTI-142580: Phase I Study of RO5541077 in Patients with B cell Non-Hodgkin s Lymphoma

Completed
1
18
Japan
Polivy (polatuzumab vedotin-piiq) - Roche
Chugai Pharmaceutical Co., Ltd.
B cell Non-Hodgkin s Lymphoma
 
 
BO42203, NCT04790903: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated
1
50
Europe, US
Venetoclax, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse
05/24
05/24
CC-220-DLBCL-001, NCT04884035: Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Recruiting
1
174
Europe, US, RoW
CC-220, Iberdomide, BMS-986382, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Prednisolone, CC-99282, BMS-986369, Polatuzumab vedotin
Celgene
Lymphoma, B-Cell
06/27
06/27
NCT04739813: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Recruiting
1
55
US
obinutuzumab, prednisone, Revlimid, Polatuzumab, ibrutinib, venetoclax
National Cancer Institute (NCI)
Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
10/25
10/30
NP40126, NCT03467373: A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Checkmark Safety and efficacy of phase 1 study in combination with R-CHOP in patients with previously untreated DLBCL
Dec 2022 - Dec 2022: Safety and efficacy of phase 1 study in combination with R-CHOP in patients with previously untreated DLBCL
Completed
1
111
Europe, Canada, US, RoW
Glofitamab, RO7082859, Obinutuzumab (G), Gazyva, Rituximab (R), Rituxan, Tocilizumab, Actemra, Cyclophosphamide, Doxorubicin, Vincristine, Oncovin, Prednisone, Polatuzumab vedotin
Hoffmann-La Roche
B-Cell Lymphoma, Non-Hodgkin Lymphoma
12/24
12/24
LOTIS 7, NCT04970901: A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Recruiting
1
200
Europe, US, RoW
Loncastuximab Tesirine, ZYNLONTA, ADCT-402, Polatuzumab Vedotin, Glofitamab, Mosunetuzumab, Obinutuzumab
ADC Therapeutics S.A.
B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
12/25
12/26
NCT06730542: Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in Patients with Secondary CNS Lymphoma

Recruiting
1
20
US
Zanubrutinib, Methotrexate, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
Juan P. Alderuccio, MD, BeiGene
CNS Lymphoma
03/30
03/30
NCT06015880: Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
1
30
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, FCU-2711, FCU2711, polatuzumab vedotin-piiq, Polivy, RG 7596, RG-7596, RG7596, Ro 5541077-000, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT
National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
06/26
06/26
NCT04323956: Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Active, not recruiting
1
50
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Asta B 518, B-518, WR-138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Parsaclisib, (4R)-4-(3-((1S)-1-(4-Amino-3-methyl-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, IBI376, INCB 50465, INCB-50465, INCB050465, INCB50465, WHO 10589, Pegfilgrastim, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, pegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv, Pegfilgrastim-jmdb, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Udenyca, Ziextenzo, Neupopeg, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Ikgdar, Mabtas, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Mayo Clinic, National Cancer Institute (NCI)
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Indolent Non-Hodgkin Lymphoma
05/26
05/27
NCT04231877: Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Recruiting
1
56
US
Polatuzumab Vedotin, 1313206-42-6, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Rituximab, 174722-31-7, 687451, ABP 798, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, IDEC-C2B8 Monoclonal Antibody, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, rituximab-abbs, Rituximab Biosimilar SIBP-02, Riabni, Rituximab ARRX, Rituximab PVVR, Ruxience, Prednisone, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Metacortandracin, Meticorten, Ofisolona, Panafcort, Paracort, Predicor, Predicorten, Prednidib, Prednilonga, Prednitone, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Cyclophosphamide, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Glofitamab, Glofitamab-gxbm, RO7082859, Multigated Acquisition Scan, MUGA Scan, MUGA, Echocardiography, EC, FDG-Positron Emission Tomography, FDG-PET, FDG-PET Imaging, Computed Tomography, CAT Scan, CT Scan, Computed Axial Tomography, Bone Marrow Biopsy, Biospecimen Collection, Bone Marrow Aspiration
University of Washington, Genentech, Inc.
Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Gray-Zone Lymphoma
12/26
12/31
POLASTAR, jRCT1071220082: Polatuzumab vedotin plus R-CHP therapy in patients with previously untreated diffuse large B-cell lymphoma

Active, not recruiting
N/A
500
Japan
Polivy (polatuzumab vedotin-piiq) - Roche, Rituxan (rituximab) - Roche, cyclophosphamide - Generic mfg., doxorubicin hydrochloride - Generic mfg., prednisone - Generic mfg.
Kyushu University Hospital, Chugai Pharmaceutical Co., Ltd.
Diffuse large B-cell lymphoma
 
 
POSS, NCT06734078: An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated with Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme

Active, not recruiting
N/A
100
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
DLBCL - Diffuse Large B Cell Lymphoma
12/25
12/25
APOLLO, ISRCTN11542980: Evaluating alternative treatment regimens for patients who have diffuse large B-cell lymphoma that is unsuitable for standard treatment

No Longer Available
N/A
56
United Kingdom, England, Scotland
Polivy (polatuzumab vedotin-piiq) - Roche
Clatterbridge Cancer Centre NHS Foundation Trust, Roche;Hoffman-La Roche
Diffuse large B-cell lymphoma
 
 
UMIN000053834: A database study on the occurrence of febrile neutropenia and other symptoms and prophylactic treatment in untreated diffuse large B-cell lymphoma, including patients aged 80 years or older

Not yet recruiting
N/A
1000
Japan
Polivy (polatuzumab vedotin-piiq) - Roche, cyclophosphamide - Generic mfg., doxorubicin hydrochloride - Generic mfg.
Chugai Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd.
Diffuse large B-cell lymphoma;Large B-Cell Lymphoma
 
 
NCT05954910: A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma

Recruiting
N/A
1000
RoW
Polatuzumab Vedotin, POLIVY ®
Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma
05/27
05/27
ChiCTR2400082122: A single-center, observational study of polatuzumab vedotin-based regimen for older patients with relapsed/refractory diffuse large B-cell lymphoma

Not yet recruiting
N/A
47
 
None; None
Beijing Hospital; Beijing Hospital, Self funding
Diffuse large B cell lymphoma
 
 
NCT04624893: A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin

Recruiting
N/A
35
RoW
Polatuzumab Vedotin-Piiq, Polatuzumab Vedotin
Jiangsu Cancer Institute & Hospital
Diffuse Large B-Cell Lymphoma (DLBCL)
12/20
12/20
SHR-A1912 / Jiangsu Hengrui Pharma
SHR-A1912-II-201, NCT06104553: A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma

Recruiting
1/2
132
RoW
SHR-A1912; R-Chemo
Shanghai Hengrui Pharmaceutical Co., Ltd.
B-cell Non-Hodgkin's Lymphoma
12/25
06/26
SHR-A1912-I-101, NCT05113069: A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas

Enrolling by invitation
1
170
RoW
SHR-A1912
Shanghai Hengrui Pharmaceutical Co., Ltd.
B Cell Lymphoma
03/24
03/25
SHR-A1904-301, NCT06350006: SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor

Recruiting
1
924
RoW
SHR-A1904; Adebrelimab, SHR-A1904; CAPOX; Adebrelimab
Shanghai Hengrui Pharmaceutical Co., Ltd.
Cldn18.2-positive Advanced Solid Tumor
12/27
12/28
ARC-02 / Araris Biotech
No trials found

Download Options